Livingston Group Asset Management CO operating as Southport Capital Management lessened its position in GlaxoSmithKline plc (NYSE:GSK) by 5.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 39,490 shares of the pharmaceutical company’s stock after selling 2,195 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in GlaxoSmithKline were worth $1,856,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in GSK. Prestige Wealth Management Group LLC bought a new stake in shares of GlaxoSmithKline in the 2nd quarter worth about $26,000. Prime Capital Investment Advisors LLC bought a new stake in shares of GlaxoSmithKline in the 3rd quarter worth about $26,000. Ellis Investment Partners LLC lifted its holdings in shares of GlaxoSmithKline by 144.5% in the 3rd quarter. Ellis Investment Partners LLC now owns 1,022 shares of the pharmaceutical company’s stock worth $43,000 after acquiring an additional 604 shares during the last quarter. Knuff & Co LLC bought a new stake in shares of GlaxoSmithKline in the 3rd quarter worth about $43,000. Finally, Gradient Investments LLC lifted its holdings in shares of GlaxoSmithKline by 192.6% in the 3rd quarter. Gradient Investments LLC now owns 1,226 shares of the pharmaceutical company’s stock worth $52,000 after acquiring an additional 807 shares during the last quarter. Hedge funds and other institutional investors own 11.27% of the company’s stock.
Several equities research analysts have recently issued reports on GSK shares. UBS Group upgraded shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating in a report on Wednesday, November 27th. Svb Leerink started coverage on shares of GlaxoSmithKline in a report on Monday, December 2nd. They issued an “outperform” rating for the company. ValuEngine upgraded shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Friday, December 20th. Cantor Fitzgerald upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, October 11th. Finally, Leerink Swann started coverage on shares of GlaxoSmithKline in a report on Monday, December 2nd. They issued an “outperform” rating and a $53.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $47.33.
Shares of NYSE GSK traded down $0.38 during trading hours on Thursday, reaching $47.23. The stock had a trading volume of 1,438,528 shares, compared to its average volume of 1,723,374. GlaxoSmithKline plc has a 52-week low of $38.16 and a 52-week high of $47.79. The firm has a market cap of $117.33 billion, a price-to-earnings ratio of 14.94, a P/E/G ratio of 3.12 and a beta of 0.68. The business’s fifty day moving average price is $46.39 and its two-hundred day moving average price is $43.12. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 1.38.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.85 by $0.10. The company had revenue of $11.57 billion for the quarter, compared to the consensus estimate of $11.34 billion. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. Equities research analysts anticipate that GlaxoSmithKline plc will post 3.25 earnings per share for the current fiscal year.
In other news, major shareholder Plc Glaxosmithkline bought 357,142 shares of the stock in a transaction on Friday, October 18th. The stock was acquired at an average cost of $28.00 per share, for a total transaction of $9,999,976.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 10.00% of the stock is currently owned by corporate insiders.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Why do commodities matter?
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.